Introduction
Treatment failures have been reported in many of the larger randomized clinical trials of wet age-related macular degeneration (AMD) with an incidence of about 10% within the first year.
1,2 Additionally, 20-30% of patients appear to respond insufficiently to treatment; [3] [4] [5] however, the underlying reasons for this remain under debate. 6 Independent of their response to treatment, the majority of patients will need continuous active treatment. The intensity of this treatment may be based on individual needs. Even under ideal conditions, long-term decline of visual acuity may occur in response to increasing age and natural progression of the underlying degenerative disease component. Insufficient response to treatment and under-treatment, on the other hand, promote the development and progression of atrophy and fibrovascular scarring and also limit the long-term functional prognosis and potential for further improvement. 7, 8 Two anti-vascular endothelial growth factor (anti-VEGF) therapies have been approved for the treatment of active exudative AMD (eAMD). These include Ranibizumab in 2006 and Aflibercept in 2011. 9, 10 None of these drugs, however, is able to control the progression of fibrovascular scarring and the development of geographic atrophy in the retinal pigment epithelium/choriocapillaris/Bruch's membrane complex, which also affects the neuroretina. 11 Even worse, these drugs may potentially contribute to more rapid progression of this degenerative process for which currently no drug has proven effective. 8, 12, 13 This advocates for a reduction in the use of anti-VEGF drugs to suit the individual needs with the aim of maintaining a dry retina. If the latter is not achieved, the aim should at least be the absence of any intraretinal and stable subretinal and sub-pigment epithelial fluid with the minimum possible number of injections.
14 Strategies to improve the outcome in cases with an unsatisfactory response to anti-VEGF drugs have been discussed; however, the pathophysiological basis for the limited response has not fully been understood. 6 The possibility of resistance to anti-VEGF drugs has been suggested, but may be of minor clinical relevance. As AMD has been linked to several independent pathological factors, including chronic oxidative stress, decline of autophagic capacity, and inflammation, [15] [16] [17] [18] [19] many potential targets for treatment are possible. Numerous attempts have been made in recent years to understand and target the inflammatory tissue response which is seen in the development of wet AMD. [20] [21] [22] It is thus surprising that, during the early days of the anti-VEGF era, only a few studies with small case numbers have been published regarding the impact of intravitreal corticosteroids (e.g. triamcinolone, dexamethasone) on disease progression in poor anti-VEGF responders. [23] [24] [25] [26] [27] [28] Few studies have since been reported on the use of steroid treatment for eAMD; most have reported on the use of combination therapy (e.g. steroids with anti-VEGF treatment). 29, 30 In a retrospective, real-world clinical study, we compare combined treatment with corticosteroids and anti-VEGF (group 1), including a dexamethasone-based implant (Ozurdex ® ) or Triamcinolone, or switch to another anti-VEGF agent (group 2) for the treatment of eAMD which has incompletely responded to anti-VEGF drugs.
Patients and Methods
This retrospective, interventional case series included patients with eAMD who responded insufficiently to prior anti-VEGF therapy. All patients were treatment naïve before anti-VEGF therapy started and primarily received anti-VEGF therapy in treat and extend regime. The decision to switch medication after insufficient response to anti-VEGF therapy was based on persisting intra-and/or subretinal fluid after 12 months of treatment or a dissatisfying treatment demand which did not allow prolongation of injection intervals beyond 6 weeks. Prior to the treatment switch, patients received either Ranibizumab (Lucentis ® , Novartis) or Aflibercept (Eylea@, Bayer) at (up to) monthly intervals in the previous 12 months. Informed consent for the planned off-label treatment was signed by each participant. Patients with inadequately controlled glaucoma (intraocular pressure >21mmHg under therapy with two drugs), clear lens, structural damage to the macula excluding functional gain, retinal detachment, retinal vascular disease (i.e. retinal vein occlusion, central retinal artery occlusion), history of cataract surgery in the previous six months, any posterior segment surgery, history of or ongoing uveitis of possible infectious origin, and any systemic disease potentially interfering with the local situation (i.e. diabetes mellitus with maculopathy) were excluded.
This study was approved by the Institutional Ethics Committee, University of Bern (reference number: 330/14). All patients had given informed consent prior to inclusion in the study for the use of their data, strictly adhering to the tenets of the Declaration of Helsinki.
Group 1 included a consecutive series of eyes that had received either: 1) a 0.7mg Dexamethasone implant (Ozurdex ® Allergan Pharmaceuticals, Westport, Ireland) within 6 weeks of their last anti-VEGF injection or 50 µL (corresponding to an estimated equivalent of 4 mg) of crystalline Triamcinolone acetonide (Kenacort ® , Dermapharm AG, Huenenberg, Switzerland) after removal of the carrier fluid intravitreally in addition to 50 µL of the anti-VEGF drug given prior to the switch in treatment protocol (i.e. Ranibizumab 0.5 mg or Aflibercept 2.0 mg). The treatment of group 2 eyes was switched to either Ranibizumab 0.5 mg (from initial therapy with Aflibercept 2.0 mg, n=6) or Aflibercept 2.0 mg (from initial therapy with Ranibizumab 0.5 mg, n=19) within 6 weeks of their last anti-VEGF injection. In the 12 months prior to treatment change, none of the patients had received any other treatment than intravitreal anti-VEGF injection. Criteria for re-injection were in both groups defined as the presence of any intraretinal fluid or instability of subretinal fluid or pigment epithelial detachment.
Measurements of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in µm, were quantified at the start of therapy, at 3, 6, and 12 months of anti-VEGF treatment prior to switch, as well as at the time of treatment switch and 3, 6, and 12 months thereafter. BCVA was performed on a Snellen scale and converted to Early Treatment Diabetic Retinopathy Study (ETDRS)-letter scores with 85 letters representing a BCVA of 1.0. CRT was measured from the inner retinal surface to Bruch's membrane by optical coherence tomography (OCT, Spectralis TM, Heidelberg Engineering, Heidelberg, Germany). Baseline values were defined using data from 12 months prior to treatment switch.
Study endpoints included the number of injections, time to re-injection, change in CRT, and ETDRS letters from 12 months prior to and 12 months after treatment switch. The aim was to assess functional stability/maintenance (maximum ETDRS letter change within ± 5 ETDRS letters) or improvement (loss or gain of >5 ETDRS letters) and anatomical response (anatomic stability/maintenance = max. change in CRT within ± 50 µm; improvement = CRT reduction ≥50 µm) under therapy.
Numerical data are presented as mean values together with the standard deviation. Nonparametric tests were used to analyze the data as the data were not normally distributed. The Wilcoxon sign-rank test was used to test the change over time within each group, and comparisons between the two groups were analyzed using the Mann-Whitney U-test. For comparison of the proportions between the groups a Chi-square test was used. A p-value of <0.05 was considered statistically significant.
Results
Forty-three eyes from 43 patients (18 in group 1 (n=7 Triamcinolone, n=11 Dexamethasone), 25 in group 2) were included. All eyes were pseudophakic. All eyes had been treated with intravitreal injections of Ranibizumab 0.5 mg or Aflibercept 2.0 mg 12 months prior to treatment switch starting with three loading doses. There were no significant differences between the two treatment groups with regard to gender, age, initial BCVA, baseline CRT, and choroidal neovascularization (CNV) type (Table 1) . Both groups showed similar proportions of persistent AMD activity (defined as presence of any intraretinal fluid or instability of subretinal fluid or pigment epithelial detachment) from 12 months prior to until 12 months after treatment switch (Table 2) .
Also, there was no difference between the two groups in terms of the total number of injections and 12-month average therapy intervals prior to treatment switch. After treatment switch, group 1 required fewer injections than group 2, which resulted in longer therapy intervals (Tables 3 and 4) .
Despite the same anti-VEGF treatment regime in both groups in the 12 months prior to treatment switch, the CRT value at 3 and 6 months before switch was higher in group 1 indicating a higher treatment demand in this group. After switch, the two groups showed no difference in CRT at 3 and 6 months. The CRT was however higher in group 1 at 12 months post-switch ( Figure 1 ). There was no difference in the time between the last injection and 12-month follow-up (group 1: 2.5±1.3, group 2: 1.9±0.6 months, p= 0.12). There was no difference in BCVA between the groups during the entire study period (Figure 2 ). There was also no difference in BCVA within group 1 (between patients treated with Triamcinolone and Dexamethasone). There were no adverse events recorded during the study period apart from three cases in group 1 with a rise in intraocular pressure (IOP) following the Dexamethasone implant. All of these cases were treated with additional anti-glaucoma drugs.
Discussion
Despite effective and well-established therapy with anti-VEGF for wet AMD, the proportion patients (20-30%) with an incomplete response or that require a high demand of anti-VEGF treatment results in a substantial burden to patients, physicians, and care givers. [27] [28] [29] Different therapeutic strategies in these challenging cases, including a switch to another anti-VEGF agent, use of corticosteroids, or use of photodynamic therapy (PDT), remain as third-line therapy options. [30] [31] [32] [33] [34] [35] To the best of our knowledge, a switch to another anti-VEGF agent is the first and most practical strategy to poor response. However, the burden increases further if this strategy also fails. In these cases, corticosteroids may be an interesting option. At the level of Bruch's membrane, an accumulation of inflammatory molecules, recruitment of macrophages, complement activation, increased VEGF expression in the retinal pigment epithelium, microglial activation, and accumulation of cellular debris all contribute to the progression of AMD and its switch to the neovascular form. [36] [37] [38] [39] All the aforementioned factors may be influenced by corticosteroids. Additionally, corticosteroids may affect the endothelial cells by regulating tight junction proteins and limiting VEGF expression through glucocorticoid receptor activity. 40, 41 Our retrospective data suggest that corticosteroid therapy in combination with anti-VEGF treatment is effective in maintaining visual function for three to twelve months in eyes that have not achieved functional and anatomic stability under anti-VEGF monotherapy. This confirms the findings reported in other studies. [42] [43] [44] [45] [46] [47] In these difficult-to-treat, widely unresponsive cases, the need for anti-VEGF injections was reduced significantly by the addition of corticosteroids. This resulted in extension of the re-injection interval while BCVA was kept stable as compared to treatment with intensive anti-VEGF monotherapy. Thus, the desired treatment effect of reducing the treatment burden met the expectation of the treating physicians and patients. However, despite not being significant, an influence of the higher pre-switch injection load in group 1 is questionable.
Furthermore, the higher CRT values seen in group 1 after the loading phase and the first 6 months of anti-VEGF treatment indicate that the corticosteroid group may include cases with an even higher treatment demand. The difference at 12 months post-switch may be related to the larger therapy interval extension in group 1.
If a dry macula has not been achieved within 6 months of treatment initiation, it is conceivable that the treatment effect would have exceeded than that found in our study. 48 Based on careful case selection, triple therapy, including corticosteroid, anti-VEGF drugs, and photodynamic therapy with Verteporfin ® , was also suggested to improve outcomes based on the maintenance of the macular structure. 35 These data indicate that VEGF may not be the only driver of this biologically complex macular disease resulting in macular scarring and atrophy. Our results support recent findings that pseudophakic eyes with a high treatment demand or that incompletely respond to anti-VEGF treatment may benefit from combined corticosteroid and anti-VEGF treatment in order to maintain function over a period of at least 12 months with a remarkably reduced treatment burden. [42] [43] [44] [45] [46] [47] Whether the outcomes reported herein can be sustained for a longer period of time should be addressed in larger series. The interpretation of corticosteroid treatment outcomes in our series has to be undertaken with care based on our rather strict patient selection criteria resulting in a relatively small sample size. Generally, and namely in patients with instable neovascular AMD, the use of corticosteroids is limited by their side effects, namely uncontrolled rise in intraocular pressure and cataract progression.
In conclusion, single patients with an extremely high anti-VEGF treatment demand over longer periods may benefit from an attempt to use corticosteroids in order to control co-existing inflammatory tissue responses in the absence of contraindications for their use.
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